1/69
Looks like no tags are added yet.
Types of surfactants
-animal-derived
-synthetic-derived
Surfactant drug name endings
-acant
What are surfactants used to treat?
Respiratory Distress Syndrome
Bonvine Lipid Extract Surfactant brand name
BLES
Bonvine Lipid Extract Surfactant indication
Respiratory distress syndrome in premature neonates
Bonvine Lipid Extract Surfactant dosing
< 380g and > 4,460g: Endotracheal: Administer 5mL/kg/dose as soon as RDS diagnosed
-may repeat dose if needed, up to a total of 4 doses within the first 5 days of life
Bonvine Lipid Extract Surfactant BW
temporary slow heartbeat and low oxygen levels may happen with this drug
Bonvine Lipid Extract Surfactant AE >10%
-Bradycardia
-patent ductus arteriosus
-sepsis
-intraventricular hemorrhage
-retinopathy of prematurity
-decreased lung function (decrease Osats or increase CO2)
Bonvine Lipid Extract Surfactant DDI
Bradycardia causing agents (camizestrant, ceritinib, estrasimod, fexinidazole, fingolimod, ivabradine, lacosamide, landiolol, midodrine, ozanimod, ponesimod, siponimod)
Bonvine Lipid Extract Surfactant MOA
Replaces deficient or ineffective endogenous lung surfactant in neonates with respiratory distress syndrome (RDS). Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between air and alveolar surfaces.
Bonvine Lipid Extract Surfactant CI
Hypersensitivity to bovine lipid extract surfactant or any component of the formulation; active pulmonary hemorrhage.
Bonvine Lipid Extract Surfactant pt counseling
1. Used to treat lung distress in premature babies
2. SE to call Dr: trouble breathing, signs of allergic rxn, signs of infection, coughing up blood, seizures, black, tarry, or bloody stools, wheezing, slow heartbeat
3. The drug is given into the lungs with a tube
Beractant brand name
Survanta
Beractant drug class
lung surfactant
Beractant indication
RDS
Beractant dosage form
1mL of beractant contains 25mg of phospholipids
Beractant dosing
Rescue Tx Preterm neonates: endotracheal 4mL/kg following Dx of RDS
-Additional doses may be administered if patient remains intubated and requires at least 30% inspired fraction of oxygen (FiO2) to maintain adequate oxygenation
-Dosing more often than Q12H is typically not required unless surfactant is being inactivated by infectious process, meconium, or blood
-Doses should not be given more frequently than Q6H
-Up to 4 doses may be administered if evidence of respiratory distress continues.
Prophylactic therapy: routine prophylactic surfactant administration is no longer recommended
-Preterm neonates: endotracheal: 4mL/kg as soon as possible after birth, preferably within 15 minutes.
Caution with beractant
-Mucous plugs: Marked impairment of ventilation during or shortly after dosing may indicate mucous plugging of the endotracheal tube; suctioning all neonates prior to administration may decrease chance of endotracheal tube obstruction. Replace endotracheal tube immediately if obstruction is not removed with suctioning.
-Nosocomial sepsis: There is an increased risk of post-treatment nosocomial sepsis in treated neonates this increased risk was not associated with increased mortality.
-Transient adverse effects: Transient episodes of bradycardia and decreased oxygen saturation may occur. Discontinue dosing procedure and initiate measures to alleviate the condition; may reinstitute after the patient is stable. Rales and moist breath sounds may occur; endotracheal suctioning or other remedial action is necessary if clear-cut signs of airway obstruction are present.
-Intended for endotracheal administration only
-Use in neonates
-Lung oxygenation/lung compliance: Produces rapid improvements in lung oxygenation and compliance that may require frequent adjustments to oxygen delivery and ventilator settings; hyperoxia may occur within minutes of administration.
-Trained personnel: Rapidly affects oxygenation and lung compliance; restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature neonates.
AE beractant (>10%)
Bradycardia, hypertension, hypotension, vasoconstriction, pallor, oxygen desaturation, sepsis, intracranial hemorrhage, apnea, hypercapnia, low blood pCO2, pneumothorax, pulmonary emphysema
DDI of beractant
Drugs that cause bradycardia (camizestrant, ceritinib, estrasimod, fexinidazole, fingolimod, ivabradine, lacosamide, landiolol, midodrine, ozanimod, ponesimod, siponimod)
MOA of beractant
Replaces deficient or ineffective endogenous lung surfactant in neonates with respiratory distress syndrome (RDS) or in neonates at risk of developing RDS. Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between air and alveolar surfaces. /
Beractant counseling
1. Used to treat or prevent lung distress in premature babies
2. Call your doctor if you have signs of allergic reaction, trouble breathing, slow heartbeat, cough
3. This drug is given into the lungs with a tube /
Calfactant brand name
Infasurf
Calfactant drug class
lung surfactant
Calfactant dosage form
1mL of calfactant contains 35 mg phospholipid
Calfactant indication
RDS
Calfactant dosing
Rescue Tx: Newbowns
-additional doses may be administered if patient remains intubated and requires at least 30% inspired fraction of oxygen (FiO2) to maintain a PaO2 ≤80 torr
-dosing more often than every 12 hours is typically not required unless surfactant is being inactivated by an infectious process, meconium, or blood
-doses should not be given more frequently than every 6 hours
-up to 4 doses may be administered if evidence of respiratory distress continues
prophylactic therapy: routine prophylactic surfactant administration is no longer recommended
-Premature newborns (< 29 weeks gestation): endotracheal: 3mL/kg as soon as possible after birth, preferably within 30 minutes
Adminstration info of calfactant
Gently swirl vial to redisperse suspension; do not shake. Slowly draw dose into a syringe using a 20-gauge or larger needle taking care to avoid excessive foaming. Warming of vial prior to administration is not necessary.
Storage of calfactant
-store upright (3mL) and under refrigeration at 2C to 8C (36F to 46F)
-Protect from light
-Document date and time removed from refrigeration
-Unopened and unused vials of calfactant that have been warmed to room temp can be returned to refrigeration storage within 24 hours for future use; do not re-refrigerate more than one time.
-Discard unopened vials left at room temperature for >24 hours; discard unused portion after initial vial entry.
Caution with calfactant
-Transient AE: Transient episodes of bradycardia, decreased oxygen saturation, endotracheal tube blockage or reflux of calfactant into endotracheal tube may occur. Discontinue dosing procedure and initiate measures to alleviate the condition; may resume treatment with appropriate monitoring.
-For intracheal administration only
-Monitoring: Produces rapid improvements in lung oxygenation and compliance that may require frequent adjustments to oxygen delivery and ventilator settings.
-Trained personnel
AE (>10%) calfactant
bradycardia, endotracheal tube reflux, airway obstruction, cyanosis
Allergy with calfactant
calfactant allergy
Calfactant DDI
Drugs that cause bradycardia (camizestrant, ceritinib, estrasimod, fexinidazole, fingolimod, ivabradine, lacosamide, landiolol, midodrine, ozanimod, ponesimod, siponimod)
MOA of calfactant
Endogenous lung surfactant is essential for effective ventilation because it modifies alveolar surface tension, thereby stabilizing the alveoli. Lung surfactant deficiency is the cause of respiratory distress syndrome (RDS) in premature infants and lung surfactant restores surface activity to the lungs of these infants.
Counseling calfactant
-Used to treat or prevent lung distress in premature babies
-Call Dr if: signs of allergic reaction, trouble breathing new or worse, blue/gray skin color, slow heartbeat, seizures
Poractant Alfa brand name
Curosurf
Drug class of poractant alfa
lung surfactant
Indication of poractant alfa
RDS
Dosage form of poractant alfa
1mL of poractant alfa contains 76 mg of phospholipids
Dosing of poractant alfa
Preterm neonates: endotracheal: initial 2.5mL/kg/dose following a Dx of significant RDS
If pt remains intubated and continues to require oxygen to maintain adequate oxygenation, may administer 1.25 mL/kg/dose at 12-hour intervals for up to 2 additional doses.
What is the INSURE technique?
INtubate-SURfactant-Extib
Less invasive methods of surfactant administration poractant-alfa
-Minimally invasive surfactant therapy (MIST)/less invasive surfactant administration (LISA): Limited data available; optimal dose not established
-Preterm neonates: intratracheal: 1.25 to 2.5 mL/kg/dose; dosing based on trials that included infants with GA 24 to < 36 weeks; most studies allowed for repeat doses of 1.25 mL/kg if progressive RDS symptoms were noted and/or FiO2 ≥30%
-Laryngeal mask airway (LMA): Preterm neonates weighing ≥1 kg: Intratracheal: 2.5 mL/kg/dose administered in 1 to 2 mL aliquots; dosing from trials that included infants with GA 28 to <36 weeks; a repeat dose may be administered if progressive RDS symptoms and/or increased FiO2 requirements are noted
Caution with poractant-alfa
-Pulmonary hemorrhage: Pulmonary hemorrhage is a known complication of premature birth and very low birth-weight. It has been reported in both clinical trials and postmarketing reports in infants who have received poractant alfa.
-Transient AE: Transient episodes of bradycardia, decreased oxygen saturation, hypotension, or endotracheal tube blockage may occur.
-Discontinue dosing procedure and initiate measures to alleviate the condition; may reinstitute after the patient is stable.
-Administration: for intratracheal administration only
-Monitoring: Produces rapid improvements in lung oxygenation and compliance; may require frequent adjustments to oxygen delivery and ventilator settings.
-Trained personnel: Rapidly affects oxygenation and lung compliance; restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature infants.
AE (>10%) of poractant alfa
patent ductus arteriosus, bradycardia, hypotension, oxygen desaturation, obstruction of endotracheal tube
DDI with poractant alfa
Drugs that cause bradycardia (camizestrant, ceritinib, estrasimod, fexinidazole, fingolimod, ivabradine, lacosamide, landiolol, midodrine, ozanimod, ponesimod, siponimod) /
MOA of poractant alfa
Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in respiratory distress syndrome characterized by poor lung expansion, inadequate gas exchange, and atelectasis. Poractant alfa compensates for the surfactant deficiency and restores surface activity to the infant's lungs. It reduces mortality and pneumothoraces associated with RDS.
Counseling of poractant alfa
1. It is used to treat or prevent lung distress in premature babies.
2. Call Dr if: signs of allergic reaction, slow heartbeat, very bad dizziness or passing out
What drugs are antenatal corticosteroids?
-betamethasone
-dexamethasone
What does antenatal mean?
relating to the period of time before birth while a woman is pregnant
Who is given antenatal corticosteroids?
Mom
Betamethasone brand name
-Beta 1 Kit
-Celestone Soluspan
Betamethasone drug class
corticosteroid systemic
Betamethasone indication
pregnant women at risk of preterm birth to accelerate fetal lung maturity and reduce neonatal respiratory distress syndrome
Betamethasone dosing
12 mg IM every 24 hours for a total of 2 doses
When is a single course of betamethasone recommended?
patients between 24 to 34 weeks gestation, including those with ruptured membranes or multiple gestations, who are at risk of delivering within 7 days.
A single repeat course of betamethasone may be considered in some pts with:
pregnancies less than 34 weeks' gestation at risk for delivery within 7 days and who had a course of antenatal corticosteroids >14 days prior
Betamethasone administration
intramuscular route as part of a standard clinical course to promote fetal lung maturation. Shake well prior to use.
Betamethasone AE (>10%)
-CV: bradycardia, cardiac arrhythmia, cardiomegaly, circulatory shock, edema, embolism, HTN, hypertrophic cardiomyopathy
-Derm: acne, allergic dermatitis
-Endocrine: Cushing syndrome
-GI: abdominal distention, change in bowel habits, hiccups, increased appetite
-GU: bladder dysfxn, glycosuria, spermatozoa disorder
-Heme/onc: petechia
-Hepatic: hepatomegaly
-Infection
Betamethasone CI
hypersensitivity to any component of the formulation. IM administration contraindicated in immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura)
Betamethasone MOA
Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation
Betamethasone DDI
Abrocitinib, aldesleukin, Allogeneic Regulatory T Cell Immunotherapy with HSPC and T Cells, Baricitinib, BCG products, brivudine, CAR-T Cell Immunotherapy, live vaccines, Cladribine, Coccidioides immitis Skin Test, COVID-19 Vaccine (mRNA), Delgocitinib, denosumab, desmopressin, immune checkpoint inhibitors, macimorelin, mifamurtide, mifeprostone,
Betamethasone patient counseling
1. It is used for many health problems like allergy signs, asthma, adrenal gland problems, blood problems, skin rashes, or swelling problems. This is not a list of all health problems that this drug may be used for. Talk with the doctor.
2. Call Dr if: upset stomach or throwing up, increased appetite, weight gain, restlessness, sweating a lot, hair thinning, trouble sleeping
Betamethasone caution
-High BP (very bad HA/dizziness/passing out)
-Infection
-High BG
-Cushing's syndrome like weight gain
-Weak adrenal gland
Dexamethasone brand name
Dexabliss, Dexylt, DoubleDex, Dxevo, Hemady, TaperDex
Dexamethasone drug class
Anti-inflammatory Agent; Antiemetic; Corticosteroid, Systemic
Dexamethasone indication
pregnant women at risk of preterm birth to accelerate fetal lung maturity and reduce neonatal respiratory distress syndrome, for pts between 24 to 34 weeks of gestation, including those with ruptured membranes or multiple gestations, who are at risk of delivering within 7 days.
Dexamethasone dosing
IM 6mg Q12H for a total of 4 doses
When is a single course of dexamethasone indicated?
22 weeks' gestation or late preterm (between 34 0/7 weeks' and 36 6/7 weeks' gestation) who are at risk of delivering within 7 days.
Dexamethasone administration
Administered via the intramuscular route as a clinical equivalent to betamethasone, often selected based on availability or cost considerations.
Dexamethasone pt counseling
take with meals to help prevent GI upset